CervoMed

CRVO · NASDAQ

$2.29−$0.02 (−0.87%)TodayMarket closed · Oct 20, 7:43 PM ET

Prev close $2.31

About CRVO

CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Employees: 15
Headquarters: Boston, Massachusetts
Listed: Nov 9, 2016
Sector: Health Care
Industry: Biotechnology
Website: cervomed.com

Leadership

CervoMed executives
Name	Title	Since	Age
Joshua Boger	—	—	74
John Alam	—	2023	63
William Elder	—	—	42
Kelly Blackburn	—	—	61
Mark De Rosch	—	—	61
Marco Verwijs	—	—	—
Robert Cobuzzi	—	2020	60
Sylvie Gregoire	—	2023	64
David Quigley	—	—	58
Jane Hollingsworth	—	—	67
Jeffrey Poulton	—	—	57
Marwan Sabbagh	—	—	59
Frank Zavrl	—	—	59
Pj Kelleher	—	2024	—

Similar companies

Companies in the same industry as CervoMed

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.